Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Cell ; 184(3): 675-688.e19, 2021 02 04.
Article in English | MEDLINE | ID: mdl-33421369

ABSTRACT

CRISPR-Cas systems provide prokaryotes with acquired immunity against viruses and plasmids, but how these systems are regulated to prevent autoimmunity is poorly understood. Here, we show that in the S. pyogenes CRISPR-Cas system, a long-form transactivating CRISPR RNA (tracr-L) folds into a natural single guide that directs Cas9 to transcriptionally repress its own promoter (Pcas). Further, we demonstrate that Pcas serves as a critical regulatory node. De-repression causes a dramatic 3,000-fold increase in immunization rates against viruses; however, heightened immunity comes at the cost of increased autoimmune toxicity. Using bioinformatic analyses, we provide evidence that tracrRNA-mediated autoregulation is widespread in type II-A CRISPR-Cas systems. Collectively, we unveil a new paradigm for the intrinsic regulation of CRISPR-Cas systems by natural single guides, which may facilitate the frequent horizontal transfer of these systems into new hosts that have not yet evolved their own regulatory strategies.


Subject(s)
CRISPR-Associated Protein 9/metabolism , CRISPR-Cas Systems/genetics , Gene Expression , Homeostasis/genetics , RNA, Guide, Kinetoplastida/genetics , Autoimmunity/genetics , Base Sequence , Conserved Sequence , Down-Regulation/genetics , Models, Genetic , Mutation/genetics , Operon/genetics , Promoter Regions, Genetic/genetics , Streptococcus pyogenes/genetics , Stress, Physiological/genetics , Transcription, Genetic , Transcriptional Activation/genetics
2.
Cancer Discov ; 6(12): 1366-1381, 2016 12.
Article in English | MEDLINE | ID: mdl-27683557

ABSTRACT

Programmed death-1 (PD-1) is a coinhibitory receptor that downregulates the activity of tumor-infiltrating lymphocytes (TIL) in cancer and of virus-specific T cells in chronic infection. The molecular mechanisms driving high PD-1 expression on TILs have not been fully investigated. We demonstrate that TGFß1 enhances antigen-induced PD-1 expression through SMAD3-dependent, SMAD2-independent transcriptional activation in T cells in vitro and in TILs in vivo The PD-1hi subset seen in CD8+ TILs is absent in Smad3-deficient tumor-specific CD8+ TILs, resulting in enhanced cytokine production by TILs and in draining lymph nodes and antitumor activity. In addition to TGFß1's previously known effects on T-cell function, our findings suggest that TGFß1 mediates T-cell suppression via PD-1 upregulation in the tumor microenvironment (TME). They highlight bidirectional cross-talk between effector TILs and TGFß-producing cells that upregulates multiple components of the PD-1 signaling pathway to inhibit antitumor immunity. SIGNIFICANCE: Engagement of the coinhibitory receptor PD-1 or its ligand, PD-L1, dramatically inhibits the antitumor function of TILs within the TME. Our findings represent a novel immunosuppressive function of TGFß and demonstrate that TGFß1 allows tumors to evade host immune responses in part through enhanced SMAD3-mediated PD-1 expression on TILs. Cancer Discov; 6(12); 1366-81. ©2016 AACRThis article is highlighted in the In This Issue feature, p. 1293.


Subject(s)
CD8-Positive T-Lymphocytes/metabolism , Neoplasms/immunology , Programmed Cell Death 1 Receptor/genetics , Smad3 Protein/metabolism , Transforming Growth Factor beta1/metabolism , Animals , Cell Line, Tumor , Cytokines/metabolism , Drug Resistance, Neoplasm , Humans , Jurkat Cells , Lymphocytes, Tumor-Infiltrating/metabolism , Mice , Neoplasms/metabolism , Programmed Cell Death 1 Receptor/metabolism , Signal Transduction , Tumor Microenvironment
3.
Proc Natl Acad Sci U S A ; 109(35): E2353-60, 2012 Aug 28.
Article in English | MEDLINE | ID: mdl-22869749

ABSTRACT

Myostatin and activin A are structurally related secreted proteins that act to limit skeletal muscle growth. The cellular targets for myostatin and activin A in muscle and the role of satellite cells in mediating muscle hypertrophy induced by inhibition of this signaling pathway have not been fully elucidated. Here we show that myostatin/activin A inhibition can cause muscle hypertrophy in mice lacking either syndecan4 or Pax7, both of which are important for satellite cell function and development. Moreover, we show that muscle hypertrophy after pharmacological blockade of this pathway occurs without significant satellite cell proliferation and fusion to myofibers and without an increase in the number of myonuclei per myofiber. Finally, we show that genetic ablation of Acvr2b, which encodes a high-affinity receptor for myostatin and activin A specifically in myofibers is sufficient to induce muscle hypertrophy. All of these findings are consistent with satellite cells playing little or no role in myostatin/activin A signaling in vivo and render support that inhibition of this signaling pathway can be an effective therapeutic approach for increasing muscle growth even in disease settings characterized by satellite cell dysfunction.


Subject(s)
Activins/metabolism , Muscle Fibers, Skeletal/cytology , Myostatin/metabolism , Satellite Cells, Skeletal Muscle/cytology , Signal Transduction/physiology , Activin Receptors, Type II/genetics , Activin Receptors, Type II/metabolism , Animals , Follistatin/genetics , Follistatin/metabolism , Hypertrophy , Membrane Fusion/physiology , Mice , Mice, 129 Strain , Mice, Inbred C57BL , Mice, Transgenic , Muscle Fibers, Skeletal/metabolism , Muscle, Skeletal/cytology , Muscle, Skeletal/physiology , Organ Size , PAX7 Transcription Factor/genetics , PAX7 Transcription Factor/metabolism , Regeneration/physiology , Satellite Cells, Skeletal Muscle/metabolism , Syndecan-4/genetics , Syndecan-4/metabolism
4.
Proc Natl Acad Sci U S A ; 102(50): 18117-22, 2005 Dec 13.
Article in English | MEDLINE | ID: mdl-16330774

ABSTRACT

Myostatin is a secreted protein that normally functions as a negative regulator of muscle growth. Agents capable of blocking the myostatin signaling pathway could have important applications for treating human muscle degenerative diseases as well as for enhancing livestock production. Here we describe a potent myostatin inhibitor, a soluble form of the activin type IIB receptor (ACVR2B), which can cause dramatic increases in muscle mass (up to 60% in 2 weeks) when injected into wild-type mice. Furthermore, we show that the effect of the soluble receptor is attenuated but not eliminated in Mstn(-/-) mice, suggesting that at least one other ligand in addition to myostatin normally functions to limit muscle growth. Finally, we provide genetic evidence that these ligands signal through both activin type II receptors, ACVR2 and ACVR2B, to regulate muscle growth in vivo.


Subject(s)
Activin Receptors, Type II/metabolism , Muscle, Skeletal/growth & development , Signal Transduction/physiology , Transforming Growth Factor beta/antagonists & inhibitors , Activin Receptors, Type II/genetics , Activin Receptors, Type II/pharmacology , Animals , Ligands , Mice , Mice, Knockout , Muscle, Skeletal/drug effects , Myostatin , Organ Size
5.
Proc Natl Acad Sci U S A ; 100(26): 15842-6, 2003 Dec 23.
Article in English | MEDLINE | ID: mdl-14671324

ABSTRACT

Myostatin is a transforming growth factor beta family member that acts as a negative regulator of skeletal muscle growth. Myostatin circulates in the blood of adult mice in a noncovalently held complex with other proteins, including its propeptide, which maintain the C-terminal dimer in a latent, inactive state. This latent form of myostatin can be activated in vitro by treatment with acid; however, the mechanisms by which latent myostatin is activated in vivo are unknown. Here, we show that members of the bone morphogenetic protein-1/tolloid (BMP-1/TLD) family of metalloproteinases can cleave the myostatin propeptide in this complex and can thereby activate latent myostatin. Furthermore, we show that a mutant form of the propeptide resistant to cleavage by BMP-1/TLD proteinases can cause significant increases in muscle mass when injected into adult mice. These findings raise the possibility that members of the BMP-1/TLD family may be involved in activating latent myostatin in vivo and that molecules capable of inhibiting these proteinases may be effective agents for increasing muscle mass for both human therapeutic and agricultural applications.


Subject(s)
Bone Morphogenetic Proteins/metabolism , Metalloendopeptidases/metabolism , Metalloproteases/metabolism , Muscle, Skeletal/growth & development , Proteins/metabolism , Transforming Growth Factor beta/metabolism , Animals , Bone Morphogenetic Protein 1 , CHO Cells , Cricetinae , Female , Genes, Reporter , Luciferases/genetics , Luciferases/metabolism , Mice , Mice, Inbred BALB C , Myostatin , Protein Precursors/metabolism , Recombinant Fusion Proteins/metabolism , Tolloid-Like Metalloproteinases
SELECTION OF CITATIONS
SEARCH DETAIL
...